Elyxium Wealth LLC Purchases 2,724 Shares of Boston Scientific Corporation (NYSE:BSX)

Elyxium Wealth LLC lifted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 120.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,989 shares of the medical equipment provider's stock after purchasing an additional 2,724 shares during the quarter. Elyxium Wealth LLC's holdings in Boston Scientific were worth $503,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its stake in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares during the last quarter. Bank Pictet & Cie Europe AG grew its stake in shares of Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after buying an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE boosted its holdings in shares of Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares during the period. Proficio Capital Partners LLC boosted its holdings in shares of Boston Scientific by 40.2% during the fourth quarter. Proficio Capital Partners LLC now owns 5,333 shares of the medical equipment provider's stock worth $476,000 after purchasing an additional 1,528 shares during the period. Finally, Madison Investment Advisors LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth about $263,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Down 0.9%

Shares of BSX stock opened at $103.68 on Friday. The stock has a market cap of $153.39 billion, a P/E ratio of 75.68, a PEG ratio of 2.69 and a beta of 0.68. Boston Scientific Corporation has a 52 week low of $71.88 and a 52 week high of $107.53. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47. The company's fifty day simple moving average is $103.42 and its two-hundred day simple moving average is $101.08.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The firm's revenue was up 20.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.56 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on BSX. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Truist Financial raised their price objective on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a report on Thursday, April 24th. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Evercore ISI raised their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Twenty-two investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average target price of $116.09.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $106.97, for a total transaction of $5,348,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $19,077,243.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the transaction, the senior vice president directly owned 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 461,970 shares of company stock valued at $47,755,193 over the last three months. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.